Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Rad Laboratories

Medical stocks cruised higher Thursday led by breakouts from high-ranking players Abbott Laboratories and Bio-Rad Laboratories. The pandemic gives medical stock a chance to shine.

Coronavirus Limelight Sends These Bullish Medical Stocks Into Breakouts

Abbott Labs earnings for Q1 2020 have ABT stock rising on Thursday after the company beat EPS and revenue estimates from Wall Street.
The post Abbott Labs Earnings: ABT Stock Jumps on Q1 Beats appeared first on InvestorPlace.

Abbott Labs Earnings: ABT Stock Jumps on Q1 Beats

Ford Motor Company

Abbott Laboratories (ABT) CEO, Robert Ford on Q1 2020 Results - Earnings Call Transcript

The healthcare giant beat Wall Street expectations and continues to be a key player in the fight against COVID-19.

Here's Why Investors Liked Abbott Labs' Q1 Earnings Results

Schlumberger

Writing Covered Calls To Capture Volatility Enhanced Premiums

Abbott Laboratories Inc  said on Thursday a recent ramp up in coronavirus tests production would help it ride out a tough current quarter as the outbreak chokes demand for its other diagnostic kits.

Coronavirus test ramp-up to help Abbott weather 'toughest quarter'

ABT stock is trading at pre-pandemic levels thanks to strong earnings and a new test for coronavirus antibodies that's garnering attention.
The post Triage Your Portfolio With Abbott Laboratories appeared first on InvestorPlace.

Triage Your Portfolio With Abbott Laboratories

Abbott Laboratories (NYSE:ABT) said on Thursday that its profit in the first quarter declined by 16%. The American medical devices and healthcare company attributed the decline primarily to a tax expense.

Abbott Laboratories records a 16% lower profit in the first quarter

Uncertainties about the duration and impact of the coronavirus pandemic on its overall business compel Abbott (ABT) to suspend its full-year guidance.

Abbott (ABT) Beats on Q1 Earnings, Suspends '20 Guidance

Abbott Labs stock has completed a round trip into January's all-time high in response to the roll-out of the 13-minute COVID test.

Abbott Labs Stock at Cusp of Major Breakout

Abbott Laboratories  beat quarterly profit estimates on Thursday as stay-at-home orders prompted customers to stockpile its nutrition products but the company suspended its full-year forecast due to the coronavirus-fueled uncertainty.

Abbott beats quarterly profit, but pulls forecast on coronavirus concerns

Shares of Abbott Laboratories ABT, +2.01% gained 1.0% in premarket trading on Thursday after the company beat revenue expectations for the quarter.

Abbott's stock rises on revenue jump despite COVID-19 hit to business

Abbott Laboratories posted a 16% drop in quarterly profit on Thursday partly due to a tax expense and suspended its full-year forecast citing the uncertainty caused by the coronavirus outbreak.

Abbott posts a 16% drop in profit and suspends its 2020 forecast on coronavirus concerns

Abbott Laboratories Inc  posted a 16% drop in quarterly profit on Thursday partly due to a tax expense and suspended its full-year forecast citing the uncertainty caused by the coronavirus outbreak.

Abbott posts 16% fall in profit, suspends 2020 forecast on coronavirus concerns

AbbVie

Allergan

Bristol-Myers

And two of the three offer nice dividends, too.

3 Great Stocks That Are Still Ridiculously Cheap Right Now

Vanguard Dividend Appreciation ETF

Colgate-Palmolive

CVS Health

Johnson & Johnson

Lowe's

Medtronic

Microsoft

NIKE

PepsiCo

QUALCOMM

Texas Instruments

Walgreens

Walmart

I hold 15 Dividend Achievers. That index is available in ETF form by way of Vanguard's Dividend Appreciation Fund - ticker VIG.

My Dividend Achievers Quarterly Review. More Than Up To The Investment Challenge Of COVID-19

Apple

Apple launched a new iPhone, while the earnings reports continue to trickle in. Here's what happened in the stock market today.

Stock Market Today: Apple’s New iPhone; Abbott’s New Coronavirus Test

It is the company's third test for SARS-CoV-2, but its first that can tell if a person has recovered from it.

Abbott Rolling Out a Coronavirus Antibody Test

Shares of Abbott ABT, +0.18% were up 1.0% in trading on Wednesday morning after the company announced the launch of a serological test that can be used to detect if an individual has COVID-19 antibodies even if they never have had symptoms of the virus.

Abbott's shares rise as it launches antibody test

Abbott said it plans to distribute 4 million of the new tests by the end of this month, after an initial shipment of 1 million tests this week to U.S. customers.

Abbott announces new coronavirus antibody test that could do up to 20 million screenings in June

Look To Buy Further Dips On Abbott Laboratories

Though the magnitude of loss due to the virus outbreak in Abbott's (ABT) Core Laboratory business is still unclear, the company's point-of-care business is anticipated to generate profit.

Solid Diagnostics to Aid Abbott (ABT) Q1 Earnings Amid Crisis?

Revenues of Abbott's (ABT) Diabetes Care business, which has been, otherwise on a strong growth trajectory, are likely to have declined in Q1 due to the coronavirus-related market turbulence.

Will Low Product Revenues Impact Abbott (ABT) Q1 Earnings?

Abbott Laboratories: Good Pick In Uncertain Times

Bank of America

Citigroup

Costco

FedEx

JPMorgan Chase & Co

Kansas City Southern

Wells Fargo

The large money-center banks that will kick-off the 2020 Q1 earnings season for the sector this week have been hit hard in the ongoing downturn.

News for Abbott Labs Stock (ABT)